Investment Analysts’ Weekly Ratings Updates for ADC Therapeutics (ADCT)

A number of firms have modified their ratings and price targets on shares of ADC Therapeutics (NYSE: ADCT) recently:

• 6/8/2026 – ADC Therapeutics was downgraded by HC Wainwright from “buy” to “neutral”.
• 6/6/2026 – ADC Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/4/2026 – ADC Therapeutics had its “overweight” rating reaffirmed by Stephens. They now have a $5.00 price target on the stock.
• 6/4/2026 – ADC Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/4/2026 – ADC Therapeutics was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $2.00 price target on the stock, down from $6.00.
• 5/5/2026 – ADC Therapeutics had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $6.00 price target on the stock.
• 5/5/2026 – ADC Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $8.00 price target on the stock.

Insiders Place Their Bets

In other ADC Therapeutics news, major shareholder Redmile Group, Llc sold 2,634,506 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $3.28, for a total transaction of $8,641,179.68. Following the sale, the insider directly owned 12,666,731 shares in the company, valued at $41,546,877.68. This represents a 17.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders sold 5,880,415 shares of company stock valued at $19,641,067. Insiders own 5.40% of the company’s stock.

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.